Treatment of refractory anterior knee pain using botulinum toxin type A (Dysport) injection to the distal vastus lateralis muscle: a randomised placebo controlled crossover trial
| Autor: | P L Silbert, John W. Dunne, Swithin Song, Barbara J. Singer, Kevin P. Singer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Knee Joint Vastus medialis Vastus lateralis muscle Visual analogue scale Physical Therapy Sports Therapy and Rehabilitation Electromyography Isometric exercise Placebo Injections Intramuscular law.invention Quadriceps Muscle Young Adult Randomized controlled trial Double-Blind Method law Medicine Humans Orthopedics and Sports Medicine Botulinum Toxins Type A Pain Measurement Cross-Over Studies medicine.diagnostic_test business.industry General Medicine Original Articles Middle Aged Crossover study Arthralgia Surgery Pain Intractable Treatment Outcome Neuromuscular Agents Patient Satisfaction Female business |
| Zdroj: | British Journal of Sports Medicine |
| ISSN: | 1473-0480 0306-3674 |
| Popis: | Objectives This randomised controlled crossover trial examined the efficacy of botulinum toxin type A (BoNT-A) injection, plus an exercise programme, to remediate chronic anterior knee pain (AKP) associated with quadriceps muscle imbalance. Methods 24 individuals with refractory AKP received either BoNT-A (500 U Dysport) or the same volume saline injection to the vastus lateralis (VL) muscle and performed home exercises focusing on re-training the vastus medialis (VM) muscle. All subjects were offered open-label injection at 12 weeks. Knee-related disability (anterior knee pain scale; AKPS) and activity-induced pain (10 cm visual analogue scale) at 12 weeks were the primary outcomes. Peak isometric extensor force was recorded and normalised VL:VM ratios were derived from simultaneous surface electromyography. Selfreported pain and disability measures were collected at six time points to a mean of 20±8 months. Results 14 subjects received BoNT-A and 10 placebo injection. Improvement at 12 weeks was significantly greater for BoNT-A compared with placebo-injected subjects for the AKPS (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|